Gemina Request information

Home Company

About Gemina

Gemina Laboratories Inc. is a Vancouver-based nanobiotechnology company. Gemina develops the chemistry that helps biological molecules attach to the surfaces and gold nanoparticles used in diagnostic tests, research tools, and biopharmaceutical manufacturing.

Mission

Identify overlooked scientific domains where defensible chemistry creates affordable, protectable products with global impact.

How we work

We work with partners through evaluation, co-development, licensing and controlled supply.

History

  1. May 2020The company began operating.
  2. September 2020Our first patent was filed.
  3. Spring 2021Our first prototype was produced.
  4. August 2021We were publicly listed.
  5. May 2022We obtained our first regulatory product approval.
  6. July 2023We presented a COVID-19 lateral flow prototype on cellulose, built with our cellulose-binding streptavidin, at AACC 2023.
  7. February 2024We began a collaboration with the Georgia Institute of Technology on uniform gold nanospheres for lateral flow tests.
  8. July 2025With Georgia Tech, we presented a scalable method for making uniform gold nanospheres at ADLM 2025.
  9. May 2026After a strategic review, the company was taken private.

Team and board

Gemina brings together surface chemistry, diagnostics development and commercial experience.

Management

Robert Greene

Chief Executive Officer

Scientific founder of Gemina with a background in mineral processing, hydrometallurgy and surface chemistry. His research created the foundation of Gemina’s intellectual property. He has served as the CTO of Gemina since it was founded and now also serves as the CEO, leading the Company through its next phase of growth. He is also the co-founder of Brokkr Mineral Resources and Anodyne Chemistries, which extend his unique expertise in surface chemistry into application in mining and industrial chemistry.

Christine Buerki, PhD

Head of Research and Development

Experienced product development lead and member of the founding team at Gemina. Christine has previously worked as VP Clinical Development at Veracyte (NASDAQ: VCYT) and Director R&D at MedBioGene (TSX: MBI). She is responsible for managing all aspects of product development and driving the process of validating and extending the core intellectual property of the company.

John F. Prins

Chief Financial Officer

Background in corporate finance, private equity, business valuation, equity research. Built a $250MM financial advisory business. KPMG, CIBC, Cormark, GMP, CPA, CA

Geoff Griffiths

Commercial Lead

Former Director of Biosimilar Development at Mylan. Over 25 yrs experience in commercial development and 7 yrs biotech start-up experience.

Board

Dr. James Tansey

Chair

Has spent over 20 years at the interface of academic research and entrepreneurship, founded several companies, and serves on the boards of Dynacert, Vanadium Resources and Charitable Impact. Original executive board member of Gemina and Professor at the Sauder School of Business, UBC. James is an expert in sustainable technologies and life sciences.

Robert Greene

Chief Executive Officer and director

Stephen Shannon

Director

More than 30 years of investment experience with U.S. family offices; CEO of Shannon Capital Partners.

John Brussa

Director

Chair and Partner at BD&P Law in Calgary, with expertise in taxation, corporate reorganization, international transactions and structured finance; director of several public and private companies.

Martin Cronin

Director

Over 20 years in international diplomacy with the British Government; has served as CEO and director of several public and private companies.